These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33934342)

  • 1. An Integrated Approach for Assessing the Impact of Renal Impairment on Pharmacokinetics of Drugs in Development: Pivotal Role of PBPK Modelling.
    Rowland Yeo K; Gil Berglund E
    Clin Pharmacol Ther; 2021 Nov; 110(5):1168-1171. PubMed ID: 33934342
    [No Abstract]   [Full Text] [Related]  

  • 2. Predicting Pediatric Drug Disposition-Present and Future Directions of Pediatric Physiologically-Based Pharmacokinetics.
    Miyagi SJ; Long-Boyle JR
    Drug Metab Lett; 2015; 9(2):80-7. PubMed ID: 26031462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicology Strategies for Drug Discovery - Present and Future: Introduction.
    Humphreys WG; Will Y; Guengerich FP
    Chem Res Toxicol; 2016 Apr; 29(4):437. PubMed ID: 27087588
    [No Abstract]   [Full Text] [Related]  

  • 4. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 5. [FOOD - DRUG INTERACTIONS: TYPES AND MECHANISMS.].
    Lemina EY; Churyukanov VV
    Eksp Klin Farmakol; 2016; 79(11):41-44. PubMed ID: 29791108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting Food Effects: Are We There Yet?
    Emami Riedmaier A
    AAPS J; 2022 Jan; 24(1):25. PubMed ID: 35006448
    [No Abstract]   [Full Text] [Related]  

  • 8. A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development.
    Johnson TN; Small BG; Berglund EG; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):967-972. PubMed ID: 34288581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Models as Enablers of Precision Dosing in Drug Development: Pivotal Role of the Human Mass Balance Study.
    Rowland Yeo K; Venkatakrishnan K
    Clin Pharmacol Ther; 2021 Jan; 109(1):51-54. PubMed ID: 33220063
    [No Abstract]   [Full Text] [Related]  

  • 10. Metabolite Identification in the Preclinical and Clinical Phase of Drug Development.
    Wu Y; Pan L; Chen Z; Zheng Y; Diao X; Zhong D
    Curr Drug Metab; 2021; 22(11):838-857. PubMed ID: 34620061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of nephrotoxic compounds with embryonic stem-cell-derived human renal proximal tubular-like cells.
    Li Y; Kandasamy K; Chuah JK; Lam YN; Toh WS; Oo ZY; Zink D
    Mol Pharm; 2014 Jul; 11(7):1982-90. PubMed ID: 24495215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Recent Advances in Developmental Drug Disposition.
    Collier AC
    Drug Metab Lett; 2015; 9(2):64. PubMed ID: 26517862
    [No Abstract]   [Full Text] [Related]  

  • 13. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage Adjustments Related to Young or Old Age and Organ Impairment.
    Burris JF; Tortorici MA; Mandic M; Neely M; Reed MD
    J Clin Pharmacol; 2016 Dec; 56(12):1461-1473. PubMed ID: 27539787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
    Bouzom F; Ball K; Perdaems N; Walther B
    Biopharm Drug Dispos; 2012 Mar; 33(2):55-71. PubMed ID: 22228149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of drug toxicity in patients with renal insufficiency.
    Ponticelli C; Graziani G
    Nat Rev Nephrol; 2010 Jun; 6(6):317-8. PubMed ID: 20508669
    [No Abstract]   [Full Text] [Related]  

  • 17. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.
    Scotcher D; Jones C; Posada M; Galetin A; Rostami-Hodjegan A
    AAPS J; 2016 Sep; 18(5):1082-1094. PubMed ID: 27506526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A decade of drug metabolite safety testing: industry and regulatory shared learning.
    Luffer-Atlas D; Atrakchi A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):897-900. PubMed ID: 28797172
    [No Abstract]   [Full Text] [Related]  

  • 19. Specificity of pharmacokinetic modeling of nanomedicines.
    Lebreton V; Legeay S; Saulnier P; Lagarce F
    Drug Discov Today; 2021 Oct; 26(10):2259-2268. PubMed ID: 33892140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety pharmacology--current and emerging concepts.
    Hamdam J; Sethu S; Smith T; Alfirevic A; Alhaidari M; Atkinson J; Ayala M; Box H; Cross M; Delaunois A; Dermody A; Govindappa K; Guillon JM; Jenkins R; Kenna G; Lemmer B; Meecham K; Olayanju A; Pestel S; Rothfuss A; Sidaway J; Sison-Young R; Smith E; Stebbings R; Tingle Y; Valentin JP; Williams A; Williams D; Park K; Goldring C
    Toxicol Appl Pharmacol; 2013 Dec; 273(2):229-41. PubMed ID: 23732082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.